Sequence 3 from Patent US 20120302729

General Information


DRACP ID  DRACP01413

Peptide Name   Sequence 3 from Patent US 20120302729

Sequence  KAMQDAEVSKSDIGEVI

Sequence Length  17

UniProt ID  Q5R511  O35501  Q3ZCH0  P38647  P38646  Q5ZM98 

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01413

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C76H130N20O29S

Absent amino acids  CFHLNPRTWY

Common amino acids  ADEIKSV

Mass  210563

Pl  4.11

Basic residues  2

Acidic residues  4

Hydrophobic residues  6

Net charge  -2

Boman Index  -2967

Hydrophobicity  -25.88

Aliphatic Index  91.76

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2012/0302729 A1

Patent Title  Anticancer anti-mortalin peptide antibody.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status: Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013

Other Published ID  EP2511371A1  EP2511371A4 




DRACP is developed by Dr.Zheng's team.